首页> 外文OA文献 >Preparation of novel modified-release dosage forms of diclofenac sodium and ibuprofen.
【2h】

Preparation of novel modified-release dosage forms of diclofenac sodium and ibuprofen.

机译:双氯芬酸钠和布洛芬新型缓释剂型的制备。

摘要

Mini-matrix multiple unit dosage forms (MUDFs) of diclofenac sodium and S(+) ibuprofen have been prepared. Normal tabletting techniques were used to form the mini-matrices prior to their enclosure in hard gelatin capsules. Four natural hydrophilic gums, namely xanthan, karaya, locust bean and carrageenan gums as well as hydroxypropyl methylcellulose (HPMC) were used as the principle release-retarding agents. Various excipients - lactose, Encompress®, cellulose acetate phthalate (CAP), Veegum F® and Avicel PH101® - were added in different proportions to further modify drug release. The diclofenac sodium mini-matrices (4.5 mm in diameter) were produced by the wet granulation method. The release profiles from several encapsulated minimatrices in phosphate buffer solution (pH 7.0) showed that xanthan, karaya and locust bean gums could sustain the release of diclofenac sodium while the carrageenan gum did not produce a satisfactory sustaining effect. The rank order of decreasing swelling rate in both axial and radial dimensions was xanthan > karaya > locust bean gum and each of these gums showed almost Fickian swelling behaviour. The solvent penetration rates were consistent with the swelling rates. However, the order of decreasing drug release and erosion rates was locust bean> xanthan > karaya gum. For each of these gums, the release behaviour was anomalous indicating that both Fickian drug diffusion and polymer relaxation were involved in the release process. The dominant mechanism depended on the nature and content of the gum, as well as the stage in the dissolution period. The study involving xanthan gum showed that the diclofenac sodium release rate declined linearly with a progressive increase in the gumcontent, without changing the release behaviour. However, for high drug: xanthan gum ratio (2:1), the release kinetics changed to Super Case II. Solubility differences between the excipients did not affect the release rate, but increasing proportions of each excipient produced a faster release rate with the release mechanism changing from anomalous to Case II and then to Super Case II transport. Mini-matrices containing HPMC produced faster drug release than those containing the three natural gums. There was no synergistic effect between xanthan and locust bean gums on the release of diclofenac sodium from mini-matrices. Variation in the stirring speed (used in the dissolution apparatus) and matrix volume had little effect on drug release, whereas the pH of the dissolution medium greatly affected the release of diclofenac sodium. Following on from the studies involving diclofenac sodium, xanthan and karaya gums were used to produce mini-matrices of S(+) ibuprofen. Excipients with good compressibility characteristics such as lactose, Encompress® and Avicel PH101® were needed in the formulations. At pH 7, higher drug release rates were obtained with karaya gum (Super Case II mechanism) compared with xanthan gum (anomalous behaviour). Solubility differences between the excipients slightly affected the release rate. Compression forces (11 - 26 kN) slightly affected the crushing strength. The minimatrices were relatively stable to variation in temperature (5 - 37°C) and relative humidity (10 - 75%) over a 2 month time period. These studies have shown that near zero-order release of diclofenac sodium and S(+) ibuprofen can be achieved using encapsulated mini-matrices formulations. The release mechanisms and release rates can be adjusted by variation of the type and content of gums and/or excipients.
机译:已经制备了双氯芬酸钠和布洛芬S(+)的最小基质多单位剂型(MUDF)。在将微型矩阵封装在硬明胶胶囊中之前,使用常规压片技术形成微型矩阵。四种天然亲水胶,即黄原胶,卡拉亚胶,刺槐豆胶和角叉菜胶以及羟丙基甲基纤维素(HPMC)用作主要的缓释剂。以不同比例添加各种赋形剂-乳糖,Encompress®,邻苯二甲酸乙酸纤维素(CAP),VeegumF®和AvicelPH101®,以进一步改善药物释放。通过湿法制粒制备双氯芬酸钠微型基质(直径4.5mm)。在磷酸盐缓冲液(pH 7.0)中,几种包封的微基质的释放曲线表明,黄原胶,卡拉亚胶和刺槐豆胶可以维持双氯芬酸钠的释放,而角叉菜胶的产生却没有令人满意的维持效果。在轴向和径向尺寸上降低溶胀速率的等级顺序是黄原胶> karaya>刺槐豆胶,这些胶中的每一种都显示出几乎菲克式的溶胀行为。溶剂渗透速率与溶胀速率一致。然而,降低药物释放和侵蚀速率的顺序是刺槐豆>黄原胶>卡拉胶。对于这些口香糖中的每一种,释放行为都是异常的,这表明Fickian药物扩散和聚合物松弛都与释放过程有关。主导机理取决于树胶的性质和含量,以及溶解期的阶段。涉及黄原胶的研究表明,双氯芬酸钠的释放速率随胶含量的增加而线性下降,而没有改变释放行为。但是,对于高药物:黄原胶比例(2:1),释放动力学更改为Super Case II。赋形剂之间的溶解度差异不会影响释放速率,但是每种赋形剂的比例不断增加,释放速率更快,释放机理从异常转移到Case II,再到Super Case II。含有HPMC的微型基质比含有三种天然树胶的微型基质释放的药物更快。黄原胶和刺槐豆胶之间的协同作用对微型基质中双氯芬酸钠的释放没有影响。搅拌速度(用于溶出度仪中)和基质体积的变化对药物释放几乎没有影响,而溶出介质的pH值极大地影响了双氯芬酸钠的释放。在涉及双氯芬酸钠的研究之后,黄原胶和卡拉叶胶被用于生产S(+)布洛芬的微型基质。制剂中需要具有良好可压缩性的赋形剂,例如乳糖,Encompress®和AvicelPH101®。在pH为7时,与黄原胶(异常行为)相比,使用karaya胶(Super Case II机制)可获得更高的药物释放速率。赋形剂之间的溶解度差异会稍微影响释放速率。压缩力(11-26 kN)稍微影响了破碎强度。在两个月的时间内,最小矩阵对于温度(5-37°C)和相对湿度(10-75%)的变化相对稳定。这些研究表明,使用胶囊化的微型基质制剂可以实现双氯芬酸钠和布洛芬S(+)接近零级释放。释放机理和释放速率可以通过改变胶和/或赋形剂的类型和含量来调节。

著录项

  • 作者

    Sujja-Areevath Jomjai;

  • 作者单位
  • 年度 1997
  • 总页数
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号